MicroRNAs (miRNAs) are small B22nt single stranded RNAs that negatively regulate protein expression by binding to partially complementary sequences in the 3 0 untranslated region (3 0 UTRs) of target gene messenger RNAs (mRNA). Recently, mutations have been identified in both miRNAs and target genes that disrupt regulatory relationships, contribute to oncogenesis and serve as biomarkers for cancer risk. KIT, an established oncogene with a multifaceted role in melanogenesis and melanoma pathogenesis, has recently been shown to be upregulated in some melanomas, and is also a target of the miRNA miR-221. Here, we describe a genetic variant in the 3 Introduction Melanoma, a malignancy that arises from melanocytes (most often of the skin), is one of the least common but most fatal forms of skin cancer, representing only 3% of skin cancers but resulting in over 75% of skin-cancer deaths. An estimated 69 000 cases of melanoma were diagnosed in the US in 2009 and the incidence of this cancer is increasing (Rigel, 2010) . Melanoma is treatable if caught at the early, localized stage, with a 5-year survival rate of 99%. However, this survival rate drops to just 29% for patients diagnosed with a more advanced stage, such as an ulcerated tumor with lymph node involvement, highlighting the importance of early detection and risk assessment (Gershenwald et al., 2010) . Approximately 10% of all melanoma cases are thought to be hereditary. For example, family linkage studies identified an autosomal-dominant, melanoma gene located on chromosome 9p21.4. This gene, called CDKN2A (also known as p16 or INK4A or MTS1), accounts for up to 40% of these hereditary melanoma cases (Meyle and Guldberg, 2009 ). However, other genetic mutations accounting for inherited melanoma risk are unknown.
MicroRNAs (miRNAs) are small B22nt singlestranded RNAs that negatively regulate protein expression by partial complementary binding usually to the 3 0 untranslated region (UTR) of messenger RNAs (mRNAs) of target genes. MiRNAs have been demonstrated to have significant roles in a wide range of cellular processes including development, aging, immunity and disease. In particular, miRNAs have been identified as key players in virtually all cancers studied, acting as both tumor suppressors and oncogenes (Stefani, 2007; Medina and Slack, 2008) . Sequence conservation of miRNAs across species is strong, as is conservation of miRNA binding sites in the 3 0 UTRs of target genes (Lee et al., 2007) .
A key regulator of melanocyte development, the KIT oncogene, has recently been identified as a target of miR-221 in melanoma (Felicetti et al., 2008; Igoucheva and Alexeev, 2009) . KIT is a receptor tyrosine kinase that binds the ligand stem-cell factor, also known as mast cell growth factor and steel factor (Smalley et al., 2009b) . KIT activation drives a number of downstream pathways associated with malignant transformation, including the PI3K/AKT pathway, known to be important for melanoma progression, as well as the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and mitogen-activated protein kinase (MAPK) pathways (Smalley et al., 2009b) . It is therefore not surprising that aberrant KIT expression and signaling has been described in multiple cancers (Went et al., 2004) . For example, KIT expression is particularly robust in gastrointestinal stromal tumors, for which immmunohistochemical detection of KIT positivity is considered a prerequisite for diagnosis, and treatment of this type of cancer has seen significant success with the KIT-inhibitor Imatinib (Demetri et al., 2002) . However, the role of KIT in melanoma appears complex. KIT, which in some studies seems a promising candidate oncogene in melanoma, has in earlier work been shown to have decreased expression in a large number of cutaneous melanomas relative to primary melanocytes (Funasaka et al., 1992; Lassam and Bickford, 1992; Natali et al., 1992; Went et al., 2004) , and in some studies either exogenous reexpression of the receptor, or addition of the ligand to the culture medium of KIT-expressing melanoma cells, can inhibit growth in cell culture (Zakut et al., 1993; Huang et al., 1996 Huang et al., , 1998 . Conversely, recent studies have shown positive KIT expression in 36% of melanomas examined (Went et al., 2004) , and have demonstrated KIT signaling as the driving oncogenic event in some sub-groups of melanoma, which harbor activating mutations or amplifications of KIT (Curtin et al., 2006; Smalley et al., 2009a Smalley et al., , 2009b . In particular, KIT expression appears to be associated with acral melanoma (Curtin et al., 2006; Ashida et al., 2009) , which occurs on the distal parts of the body and mucosal surfaces. Activating mutations or amplifications of KIT have been found in 39% of mucosal and 36% of acral melanomas (Curtin et al., 2006) . Although previous trials using Imatinib to treat melanoma were negative, a body of recent work suggests that this drug and similar receptor tyrosine kinase inhibitors may have promise with respect to this class of KIT-driven cancers (Jiang et al., 2008; Ashida et al., 2009) .
Recent work from several laboratories has examined the effects of mutations in miRNAs and their targets, and have identified genetic markers of cancer risk (Mishra and Bertino, 2009) . For example, a singlenucleotide polymorphism (SNP) in the miR-146a precursor results in production of polymorphic premiRNAs from the passenger strand and predisposes to papillary thyroid carcinoma (Jazdzewski et al., 2009 ). An SNP in the miR-125b-binding site in the BMPR1B 3 0 UTR disrupts miRNA repression of this target and confers increased risk of breast cancer (Saetrom et al., 2009) . We found that a SNP in a let-7 miRNA complementary site in the 3 0 UTR of the KRAS oncogene disrupted base-pairing in the miRNA:target duplex and significantly increased risk of non-small cell lung cancer (Chin et al., 2008) and ovarian cancer (Ratner et al., 2010) . Given these examples, we speculated that 3 0 UTR variants might have roles in the development and pathogenesis of melanoma.
Here we show that a genetic variant in a miR-221 complementary site in the KIT 3 0 UTR correlates with increased risk of melanoma, specifically of the acral subtype, and propose this variant allele as a new genetic marker for acral melanoma risk.
Results
A variant allele in a miR-221 complementary site in the KIT 3 0 UTR We amplified the 3 0 UTR of the KIT oncogene from genomic DNA of 70 melanoma patients, and examined this region for sequence variability. As all but one of the available melanoma samples were taken from patients of European descent, the study was limited to this group. We found a high frequency of heterozygosity for a variant/derived 'A' allele at rs17084733 (3169G-A) (24.3%) in our samples relative to 16.7-23.3% in various European ('Caucasian') samples as reported in dbSNP (Sherry et al., 2001; Sayers et al., 2009) . The KIT 3 0 UTR has been validated as a target of miR-221 by reporter assays (Felicetti et al., 2008; Igoucheva and Alexeev, 2009) , and three binding sites have been proposed on the basis of computational prediction software. The variant allele at rs17084733 (referred here as the KIT variant) is predicted to disrupt base pairing within the seed region of the 5 0 -most miR-221 complementary site (He et al., 2005) (Figure 1a) . Interestingly, the KIT variant was previously reported in a study examining the correlation between high miR-221 and low KIT expression in papillary thyroid carcinoma (He et al., 2005) . Out of 10 patients with low levels of KIT protein and gene transcript, five were heterozygous at rs17084733, an observation that conflicts with the hypothesis that this KIT variant would result in increased expression of KIT. Significantly, this miR-221 complementary site is highly conserved in mammals, with the site of rs17084733 being most conserved, and with the least conserved base lying at a site not predicted to base-pair in the miR-221:target duplex ( Figure 1b ).
The frequency of the variant allele in worldwide populations As reported above, rs17084733 is a locus with low frequency of heterozygosity in the dbSNP and HapMap databases. To verify that the frequency of the rs17084733 variant in melanoma exceeded that of the general population and may therefore be a marker of melanoma risk, we examined the genotype of this locus in 2765 healthy individuals from 58 groups around the world representing African, Southwest Asian, European, Siberian, Central Asian, Pacific Islander, East Asian, North American and South American populations from the Kidd collection at Yale (Rajeevan et al., 2005; Speed et al., 2009) . We found that the frequency of the variant allele differed considerably among geographic regions as well as among populations within a single region. The allele was rare to absent in Native Americans and some other populations but was the globally most frequent (43.2%) in a sample of individuals from Papua New Guinea. Within Europe the frequency of the variant allele in most populations was about 10%, but ranged from 1.5% in Finns to 22.9% in Sardinians. The frequency of the variant in this specific sample of European Americans was 10.3% ( Figure 2 ). Our melanoma samples had an allelic frequency of 12.9%, representing a 29.0% and 25.2% increase in frequency of this allele relative the European average and European Americans, respectively. However, given the range of frequencies observed, we concluded that a control population closely representative of the population from which the melanoma samples were gathered was required. Note that above, we are reporting allelic frequency rather than frequency of heterozygosity to account for rare homozygotes for this KIT variant in large worldwide populations.
Case-control analysis of the KIT variant in melanoma demonstrates increased melanoma risk in carriers of the variant allele As all of our melanoma patients were taken from a Yale/New Haven Hospital patient cohort, we assembled a control for our specific study panel taken from healthy individuals from the same community (Supplementary Table 1 ). We found a frequency of heterozygosity of the variant allele to be 16.0% (n ¼ 94) in this population, whereas the frequency of heterozygosity in melanoma patients is 24.6% (n ¼ 69), demonstrating a statistically significant 53.8% increase in the frequency of heterozygosity for this allele in patients with melanoma (P ¼ 0.02) (Figure 3 ). The odds ratio for the frequency of heterozygosity in melanoma patients relative to controls, adjusted for gender and age, is 3.30 (95% confidence interval (1.27, 8.86)) indicating that the presence of this KIT variant more than triples the risk for melanoma. Taken together these data indicate that this KIT variant may be a strong predictive marker for increased risk of melanoma.
The presence of the variant allele correlates specifically with increased risk of acral melanoma As recent work has indicated that KIT expression is associated with acral melanomas, we had included several tumors of this subtype in our initial patient pool. To determine whether this variant is particularly associated with acral melanoma we compared the frequency of heterozygosity of the KIT variant in acral and non-acral subtypes (Supplementary Table 1 ). Figure 2 Allelic frequency of the rs17084733 variant allele in 58 populations for a total of 2765 individuals. The sample sizes and allele frequencies for each population can be found in ALFRED (http://alfred.med.yale.edu) using the rs# as a keyword (Rajeevan et al., 2005) .
We found the frequency of heterozygosity of the KIT variant in non-acral samples to be 22.0% (n ¼ 41), demonstrating a 38% increase relative to controls; however, this difference is not statistically significant (P ¼ 0.070). In contrast, the frequency of heterozygosity in the acral subtype was 28.6% (n ¼ 28), demonstrating a 78.8% increase in the frequency of heterozygosity of this KIT variant in these cancers relative to controls, with an odds ratio of 4.24 (95% confidence interval (1.25, 14.65) P ¼ 0.02), indicating that this KIT variant may be a strong marker specifically for risk of acral melanoma (Figure 3) .
KIT mRNA and protein in samples harboring the variant allele To determine the impact of the variant on KIT expression we examined whether the presence of the variant allele correlated with altered levels of KIT mRNA and protein levels in melanoma. Microarray gene-expression analyses revealed significantly higher levels of KIT mRNA in samples heterozygous for the variant allele relative to non-variant samples (Figure 4) . Although sample numbers were low for these experiments, the maginitude of the difference in expression levels far overcomes the sample size. Similarly, Westernblots analyses showed that 60% of samples heterozygous for the KIT variant allele were positive for KIT expression, compared with only 24% of non-variant samples, suggesting that the presence of the KIT variant may result in increased expression of KIT protein.
However, given the binary nature of either positive or negative KIT expression and sample size, we present this as a correlation rather than a statistically significant difference ( Figure 5 ). We also found that the expression of miR-221 was slightly higher in patients carrying the variant allele, (Supplementary Figure 2, Supplementary  Table 2) , however, this difference was not statistically significant. Additionally, miR-221 expression was not decreased in the KIT-positive samples relative to the KIT-negative samples in either the non-variant or variant group suggesting that the increase in KIT expression in the variant relative to the non-variant group is not merely because of a decrease in expression of miR-221 (Supplementary Figure 3) .
Reporter assays indicate that the variant allele disrupts KIT 3 0 UTR-mediated translational repression To determine how the variant allele affects KIT expression in vitro, we designed two constructs in which the 3 0 UTR of KIT was cloned into a Renilla luciferase reporter, with and without the KIT variant. These constructs were transfected into the 501 mel melanoma cell line, which expresses miR-221 (1.7-fold increase in expression relative to average of melanoma samples tested, (Supplementary Table 2) ), and assayed for luciferase activity. The studies demonstrated a 6.7-fold increase in luciferase activity in the presence of the variant allele relative to the common allele (normalized to internal vector Firefly luciferase control, P ¼ 0.0233) (Figure 6a ). To test if this derepression depended on miR-221 and the 5 0 miR-221-complemntary site, we knocked out both of the 3 0 miR-221 complementary sites in the KIT 3 0 UTR within the above vectors and cotransfected them into the YUSAC2 melanoma cell line along with exogenous miR-221 pre-miR. These studies demonstrated a 1.24-fold increase in luciferase activity in the presence of the variant allele relative to the common allele with downstream miR-221-binding sites knocked out (normalized to scrambled pre-miR control and internal firefly luciferase control, P ¼ 0.0389) (Figure 6b) . Thus, the variant allele causes de-repression of the KIT 3 0 UTR in vitro and may allow increased KIT expression in vivo.
The variant allele is not linked to known KIT-activating mutations KIT activating mutations have been identified in exons 11, 13 and 17 of the coding region. To determine if the variant at rs17084733 might be merely a bystander linked to one of these mutations, these exons were sequenced in 10 samples carrying the variant allele. No mutations were found.
The variant allele occurs in the germline of patients As rs17084733 has been previously reported as a human SNP and occurs in the germline globally (Figure 2 ), this strongly suggests that this SNP is a germline variant, and not a somatic mutation that arose a new in the melanomas of the patients. To confirm this hypothesis we obtained paired normal lymphocytes for 11 of our melanoma samples heterozygous for the rs17084733 variant. Of these, 10 (91%), also carried this KIT variant, strongly supporting the hypothesis that this is overwhelmingly a germline variant, and thus a potential genetic marker for melanoma risk.
Discussion
Here we demonstrate that a variant in the seed region of a miR-221 complementary site in the 3 0 UTR of the KIT mRNA correlates with a greater than fourfold increase in risk for the development of acral melanoma. Significantly, the acral sub-type has recently been shown to be associated with high levels of KIT expression. We additionally show that the presence of this KIT variant may lead to increased expression of KIT as Figure 6 Reporter assays demonstrate an increase in expression from a construct containing the KIT variant relative to a construct carrying the ancestral allele. (a) Relative luciferase activity normalized to internal vector controls in 501 mel cells transfected with nonvariant (NV) and variant (V) containing KIT 3 0 UTR reporter constructs indicate a statistically significant 6.7-fold increase in reporter expression from the construct containing the KIT variant, providing evidence that this KIT variant may result in increased expression of KIT. (b) Relative luciferase activity normalized to scrambled pre-miR control and internal vector controls in YUSAC2 cells co-transfected with non-variant and variant containing KIT 3 0 UTR reporter constructs with downstream miR-221 binding sites knocked out and miR-221 pre-miR also indicate a statistically significant 1.2-fold increase in luciferase activity from the construct containing the KIT variant. evidenced through luciferase reporter constructs, which is likely because of decreased base pairing in the seed region of the miRNA:target duplex. Furthermore, this polymorphism is associated with increased KIT mRNA and protein levels in the majority of samples that harbor it. This work therefore identifies this KIT variant as a novel genetic marker for risk of acral melanoma, and suggests a mechanism through KIT misregulation.
Recent work by several groups presents a convincing argument for a significant oncogenic role for the KIT oncogene in at least some sub-classes of melanoma, renewing interest in KIT as a possible therapeutic target in these types, and highlighting the potential of KIT mutations to serve as biomarkers for melanoma risk. Multiple studies have found increased KIT expression in acral tumors lacking KIT amplifications or mutations (Curtin et al., 2006; Smalley et al., 2008) , suggesting other forms of KIT misregulation. KIT is critical for the survival, proliferation and migration of melanocytes and precursor cells, and a mouse model of forced expression of constitutively active KIT in melanocytes exhibited increased migration of these cells (Alexeev and Yoon, 2006) . These properties combined with its known oncogenic capabilities in other tissues highlight KIT as a candidate for a role in the development and pathogenesis of melanoma. However, work showing that KIT expression declined rather than increased in melanomas relative to primary melanocytes (Funasaka et al., 1992; Lassam and Bickford, 1992; Natali et al., 1992) , and that exogenous expression of KIT in some KIT-negative melanomas, or the addition of the KIT ligand to KIT-positive melanoma cells, could induce apoptosis (Zakut et al., 1993; Huang et al., 1996 Huang et al., , 1998 , runs contrary to this hypothesis. One study further showed that KIT is a target of the miRNA miR-221 and that expression of this miRNA increases over the progression of melanoma subsequent to silencing of its repressor PZLF, leading to downregulation of KIT expression (Felicetti et al., 2008; Igoucheva and Alexeev, 2009) .
However, given the robust oncogenic role of KIT in other cancers, combined with the genetic and histological complexity and diversity of melanoma as a cancer class, it is possible that KIT has a transforming or pro-proliferative role in particular subtypes of melanoma, or at particular points in the transformation process, progression, migration or metastasis of the disease. Ours and other recent data support this hypothesis. KIT positivity has been shown in some sub-classes of melanoma, in the presence and absence of amplifications and activating mutations of KIT, particularly in the acral and mucosal subtypes (Curtin et al., 2006; Smalley et al., 2009b) . In one report, KIT expression was found in melanomas that lack the activating V600E BRAF mutation (Curtin et al., 2006) , the most common oncogenic mutation identified in melanomas, found in 42% of tumors (see COSMIC Database, Wellcome Sanger Trust), although this is not the case in our cohort of melanoma where KIT expression did not correlate with BRAF mutation status (Halaban, unpublished) . However, of the 11 samples in our study harboring the KIT variant that were typed, only two (18%) carried BRAF mutations. Interestingly, one study described a group of KIT and cyclindependant kinase 4-positive melanomas with high levels of activated phospho-KIT that did not carry KIT mutations, and showed no evidence of a stem-cell factor/KIT autocrine loop, and yet exhibit high levels of activated phospho-KIT (Smalley et al., 2008) . The authors suggest that signaling activity may have arisen from high KIT-expression levels leading to spontaneous dimerization and activation of this receptor. Similarily, when we examined KIT phosphorylation status in wildtype samples and samples harboring the KIT variant, samples harboring the variant allele were phosphorylated more often and to a greater degree than wild-type samples (P ¼ 0.028) (Supplementary Figure 1) . We therefore speculate that the high expression of the protein within these cells due to repression inhibition in the presence of the variant allele may be sufficient to promote autoactivation of KIT; however, further work is required to investigate this hypothesis.
Another study presented compelling evidence of a requirement for a specific epigenetic environment for KIT-dependent transformation, demonstrating that in some melanomas KIT cooperates with a hypoxiainducible factor to activate the downstream Ras/Raf/ Mek/Erk pathway, and that in the absence of hypoxia or exogenous expression of this factor, KIT was unable to induce transformation of melanocytes (Monsel et al., 2009) . These authors speculate that this could contribute to the apparent tissue specificity of KIT-driven melanomas, for example, if hypoxic conditions exist in the extremities of the hands and feet where KIT-associated acral melanomas can occur. Of particular note, many melanomas expressing high levels of KIT have shown considerable response to the KIT inhibitor Imatinib both in cell-culture and xenograft models (Smalley et al., 2008) . Two patients presenting with metastatic melanoma exhibiting strong KIT expression showed significant response to treatment with Imatinib (Hodi et al., 2008; Lutzky et al., 2008) . Phase II trials are currently underway for Imatinib treatment of patients with activating KIT mutations (Smalley et al., 2009b) .
Our new work identifies a novel genetic marker for risk of acral melanoma, and presents a mechanism through misregulation of the KIT oncogene. Screening for the presence of this KIT variant may aid in early identification of at-risk patients, and may also be useful in predicting patients with enhanced response to treatment with receptor tyrosine kinase inhibitors, a hypothesis that warrants testing.
Materials and methods

Sample populations
Tumor and case-control samples were from patients with a diagnosis of melanoma and from healthy individuals, respectively (Supplementary Table) , and were collected with patients' signed informed consent according to a protocol approved by the Yale University Human Investigation Committee. Tissue was collected from 70 melanoma patients and 94 controls. To determine the worldwide frequency of the KIT variant alleles, 2765 individuals were genotyped from a global sample of 58 populations. According to population ancestry and geographic locations, these 58 populations are categorized into nine groups: African, Southwest Asian, European, Siberian, Central Asian, Pacific Islander, East Asian, North American and South American. Sample descriptions and samples sizes can be found in the Allele Frequency Database by searching for the population names (Rajeevan et al., 2005) . DNA samples were extracted from lymphoblastoid cell lines established and/or grown in the Yale University laboratory of KKK. The methods of transformation, cell culture and DNA purification have been described (Anderson and Gusella, 1984) . All volunteers were apparently normal and otherwise healthy adult males or females, and samples were collected after receipt of appropriate informed consent. 
SNP genotyping assays
For high-throughput genotyping of the rs17084733 locus, DNA was isolated from patient tumor and control samples as above, and was analyzed using a Taqman PCR-based SNP assay specific for rs17084733 (Assay #: C__34674348_10 Applied Biosystems, Carlsbad, CA, USA; context sequence: 5 0 -AACTGTATATATTCCCAATAGCAAC[A/G]TAGCTTC TACCATGAACAGAAAACA-3 0 ) according to manufacturer's instructions. Reactions were performed in a 25 ml volume with 12.5 ml of 2Â Taqman Genotyping Master Mix (Applied Biosystems), 1.25 ml of 20 Â of the SNP assay probe mixture (above) and 25 ng of purified DNA. Initial testing of the assay was performed by genotyping the 25 previously sequenced patient DNA samples as control, resulting in 100% accuracy relative to sequencing results for this locus. Subsequent assays were performed with the following controls: one reaction with water replacing DNA as negative control, one pre-sequenced wild-type sample and one pre-sequenced sample heterozygous for rs17084733. Reactions were run in 96-well plates on the Applied Biosystems 7900HT Fast Real-Time PCR System, cycling conditions: 1 cycle of 50 1C for 2 min, 95 1C for 10 min; 40 cycles of 95 1C for 15 s, 60 1C for 1 min. Genotypes were analyzed using the Applied Biosystems SDS genotyping software. The Kidd population samples were typed using the same TaqMan assay but in 3 ml reactions in 384-well plates also using an AB 7900HT and AB STS software but slightly different reagent proportions and cycling conditions. KIT 3 0 UTR reporter construct A psiCHECK-2 (Promega, Madison, WI, USA) derivative containing the entire KIT 3 0 UTR (wild-type KIT) was generated as follows. The KIT 3 0 UTR was amplified from human genomic DNA isolated as above using primers that included an XhoI and a NotI restriction site at the 3 0 and 5 0 ends of the UTR respectively (3 0 end primer (SG43b): 5 0 -AAAAAAAActcgagGCAGAATCAGTGTTTGGGTCA-3 0 , 5 0 end primer (SG44b): 5 0 -AAAAAAAAgcggccgcTTGATT TATATATGTACATTTTATTAG-3 0 ). This fragment was cloned into a TOPO vector using the TOPO TA Cloning Kit (Promega) as according to the manufacturers instructions and then sub-cloned into the psiCHECK-2 vector using the XhoI and a NotI sites in the multiple cloning site downstream from the Renilla luciferase coding region. The mutant variant was generated in the TOPO clone using the site-directed mutagenesis system GeneTailor (Invitrogen, Carlsbad, CA, USA) as according to the manufacturer's instructions using mutagenic primers specific for rs17084733 (forward mutagenesis primer (SG49b): 5 0 -ATTCCCAATAGCAACaTAGCTTCTACCAT-3 0 , reverse mutagenesis primer (SG50b): 5 0 -GTTGCTATTGGG AATATATACAGTTGGAA-3 0 ) and subsequently sub-cloned into the psiCHECK-2 vector as above. Vectors were sequenced as above, using 600 ng DNA. Vectors with downstream miR-221 binding sites knocked out were generated in the TOPO clone using the site-directed mutagenesis system GeneTailor (Invitrogen) as according to the manufacturer's instructions using mutagenic primers to replace the seed with adenosine repeats (site 1: forward mutatgenesis primer (SG100): 5 0 -TTG GATTCTTAAAAAAAAGGAAATAAAGTATAGG-3 0 , reverse mutagenesis primer (SG105): 5 0 -AAGAATCCAAACTAAGATG GCAGTGTTTTCCCACTCC-3 0 ; site 2: forward mutatgenesis primer (SG102): 5 0 -GTAAATATTGAAAAAAAAAAATAAT GTC-3 0 , reverse mutatgenesis primer (SG103): 5 0 -TTCAATTT TACAAAAAAAGCCAC-3 0 ) and subsequently sub-cloned into the psiCHECK-2 vector as above. Vectors were sequenced as above, using 600 ng DNA.
Cell culture and transfection A total of 501 mel and YUSAC2 melanoma cells were cultured in OptiMEM (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum and penicillin/ streptomycin (Invitrogen). For reporter expression assays, the cells were seeded in 6-well plates at 10 5 cells per well, grown for 48 h and transfected using DMRIEC transfection reagent (Invitrogen) according to the manufacturer's instructions. Cells were incubated with DMRIEC transfection reagent (6.25 ml) and plasmid DNA (250 ng) encoding either nonvariant or variant KIT reporter constructs in OptiMEM (Invitrogen) in a final volume of 0.5 ml per well for 5 h. OptiMEM (0.5 ml) supplemented with 10% fetal bovine serum was then added to each well, cells were incubated for 48 h and collected for luciferase assay. Reporter expression was measured using the Dual-Luciferase Reporter Assay (Promega) according to the manufacturer's instructions.
